
    
      All subjects will participate in a lead-in period, and qualifying subjects will continue into
      a short-term randomized treatment period. Subjects who complete the short-term period will be
      eligible to enter the long term extension period. Also, subjects who have an elevated blood
      sugar that requires additional medication for blood sugar control will be eligible to receive
      open-label metformin added onto their blinded study medication
    
  